Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on BioMarin to $125 from $120 and keeps a Buy rating on the shares after the company reported Voxzogo FY22 revenue of about $169M, at the upper end of the guidance established in Q3, and also reiterated its commitment to GAAP profitability and unveiled preliminary clinical data on BMN255 and BMN331.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin announces data from follow up from Phase 3 GENEr8-1 study of ROCTAVIAN
- BioMarin price target raised to $200, added to ‘US 1 List’ at BofA
- BioMarin’s application for Voxzogo in achondroplasia validated by EMA
- BioMarin price raises ‘more aggressive’ in 2023, says Piper Sandler
- BioMarin price target raised to $120 from $100 at Jefferies
